Optimizing Ventana chromogenic dual in-situ hybridization for mucinous epithelial ovarian cancer

被引:1
|
作者
Li X. [1 ]
Chew S.-H. [2 ]
Chay W.-Y. [3 ]
Lim-Tan S.-K. [2 ]
Goh L.-K. [4 ,5 ]
机构
[1] School of Biological Sciences, Nanyang Technological University, Singapore
[2] Department of Pathology, KK Women's and Children's Hospital, Singapore
[3] Department of Medical Oncology, National Cancer Centre, Singapore
[4] Cancer and Stem Cell Biology, Duke-National University of Singapore, Singapore
[5] Saw Swee Hock School of Public Health, National University of Singapore, Singapore
关键词
Dual in-situ hybridization; Fluorescence in-situ hybridization; Formalin-fixed paraffin-embedded tissue; Human epidermal growth factor 2; Mucinous epithelial ovarian cancer; Optimization protocols;
D O I
10.1186/1756-0500-6-562
中图分类号
学科分类号
摘要
Background: Dual in-situ hybridization (DISH) assay is a relatively new assay for evaluating Human Epidermal Growth Factor Receptor 2 (HER2) genomic amplification. Optimization protocol for the assay is not yet well established, especially for archival tissues. Although there is a recommended nominal protocol, it is not suited for formalin-fixed and paraffin-embedded (FFPE) samples that were archived for long periods. Findings. In a study on local population of mucinous epithelial ovarian cancer, we developed a series of optimization protocols based on the age of samples to improve success of the DISH assay. A decision workflow was generated to facilitate individualization of further optimization protocols. The optimizations were evaluated on 92 whole tissue sections of FFPE mucinous ovarian tumors dating from 1990 to 2011. Overall, 79 samples were successfully assayed for DISH using the series of optimization protocols. We found samples older than 1 year required further optimization beyond the nominal protocol recommended. Thirteen samples were not further assayed after first DISH assay due to inadequately preserved nuclear morphology with no ISH signals throughout the tissue section. Conclusion: The study revealed age of samples and storage conditions were major factors in successful DISH assays. Samples that were ten years or less in age, and archived in-house were successfully optimized, whereas older samples, which were also archived off-site, have a higher frequency of unsuccessful optimizations. The study provides practical and important guidelines for the new DISH assay which can facilitate successful HER2 evaluation in ovarian cancers and possibly other cancers as well. © 2013 Li et al.; licensee BioMed Central Ltd.
引用
收藏
相关论文
共 50 条
  • [1] Dual-colour chromogenic in-situ hybridization is a potential alternative to fluorescence in-situ hybridization in HER2 testing
    Hwang, Cheng-Cheng
    Pintye, Mariann
    Chang, Liang-Che
    Chen, Huang-Yang
    Yeh, Kun-Yan
    Chein, Hui-Ping
    Lee, Nin
    Chen, Jim-Ray
    [J]. HISTOPATHOLOGY, 2011, 59 (05) : 984 - 992
  • [2] HER2 status in invasive breast cancer: Immunohistochemistry, fluorescence in-situ hybridization and chromogenic in-situ hybridization
    Shirsat, Hemlata S.
    Epari, Sridhar
    Shet, Tanuja
    Bagal, Rajani
    Hawaldar, Rohini
    Desai, Sangeeta B.
    [J]. INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY, 2012, 55 (02) : 175 - 179
  • [3] Comparison of dual-colour chromogenic in-situ hybridization and fluorescence in-situ hybridization in the assessment of HER2 gene amplification in breast carcinoma
    Conlon, Susan
    Colgan, Aoife
    Allen, David
    O'Grady, Anthony
    Kay, Elaine W.
    [J]. HISTOPATHOLOGY, 2011, 58 (02) : 320 - 321
  • [4] Chromogenic in-situ hybridization:: a viable alternative to fluorescence in-situ hybridization in the HER2 testing algorithm
    Hanna, WM
    Kwok, K
    [J]. MODERN PATHOLOGY, 2006, 19 (04) : 481 - 487
  • [5] DUAL TEMPERATURE IN-SITU HYBRIDIZATION
    WEIER, HUG
    GREULICH, KM
    YOUNG, DM
    [J]. BIOTECHNIQUES, 1995, 19 (03) : 364 - 366
  • [6] Chromogenic in situ hybridization for Her-2/neu-oncogene in breast cancer: comparison of a new dual-colour chromogenic in situ hybridization with immunohistochemistry and fluorescence in situ hybridization
    Mayr, Doris
    Heim, Sibylle
    Weyrauch, Kerstin
    Zeindl-Eberhart, Evelyn
    Kunz, Anne
    Engel, Jutta
    Kirchner, Thomas
    [J]. HISTOPATHOLOGY, 2009, 55 (06) : 716 - 723
  • [7] Chromogenic and fluorescent in situ hybridization in breast cancer
    Lambros, Maryou B. K.
    Natrajan, Rachael
    Reis-Filho, Jorge S.
    [J]. HUMAN PATHOLOGY, 2007, 38 (08) : 1105 - 1122
  • [8] HER2 Chromogenic Dual In-Situ Hybridization in Cytology Cell Blocks of Breast Cancer Specimens: Is It Better Than FISH?
    Pandva, Dimple
    Oen, Handy
    Bullock, Nyasha
    Rudomina, Dorota
    Serrette, Rene
    Zheng, Tao
    Ross, Dora
    Edelweiss, Marcia
    [J]. LABORATORY INVESTIGATION, 2015, 95 : 60A - 60A
  • [9] HER2 Chromogenic Dual In-Situ Hybridization in Cytology Cell Blocks of Breast Cancer Specimens: Is It Better Than FISH?
    Pandya, Dimple
    Oen, Handy
    Bullock, Nyasha
    Rudomina, Dorota
    Serrette, Rene
    Zheng, Tao
    Ross, Dara
    Edelweiss, Marcia
    [J]. MODERN PATHOLOGY, 2015, 28 : 60A - 60A
  • [10] Gabor Features for the Classification and Evaluation of Chromogenic In-Situ Hybridization Images
    Pavlov, Stoyan
    Momcheva, Galina
    Burlakova, Pavlina
    Atanasov, Simeon
    Stoyanov, Dimo
    Ivanov, Martin
    Tonchev, Anton
    [J]. CONTEMPORARY METHODS IN BIOINFORMATICS AND BIOMEDICINE AND THEIR APPLICATIONS, 2022, 374 : 375 - 383